BC001 Combined TAS-102 in a multicenter phase II clinical study in patients with metastatic colorectal cancer who have failed or not tolerated first-and second-line standard therapy
收藏NIAID Data Ecosystem2026-03-14 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/86191
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Experimental group:BC001 combined with TAS-102 treatment
Primary outcome(s): BC001 Safety of combined TAS-102 in patients with metastatic colorectal cancer who failed or tolerated first-line and second-line standard treatment, including: adverse events, blood routine, blood chemistry and urine routine, physical examination, vital signs and electrocardiogram results.
Study Design: Single arm
创建时间：
2023-03-15
